Literature DB >> 630961

Clinical toxocity of theophylline in relation to cigarette smoking. A report from the Boston Collaborative Drug Surveillance Program.

H J Pfeifer, D J Greenblatt.   

Abstract

Adverse reactions to derivatives of theophylline were studied among 2,766 medical inpatients. The primary diagnosis at discharge was cardiac disease in 23 percent, chronic obstructive pulmonary disease in 22 percent, asthma in 13 percent, pulmonary infection in 10 percent, and other disorders in 3 percent of the patients. Eight hundred seven of the patients were current cigarette smokers, and 1,209 denied smoking. Adverse effects of administration of theophylline were reported in 298 patients (10.8 percent). Gastrointestinal disturbances, reported in 7.8 percent of the recipients, were the most common adverse effects. Others were cardiovascular disturbances (1.2 percent), effects on the central nervous system (0.9 percent), and miscellaneous adverse reactions (0.9 percent). A higher frequency of adverse reactions was associated with higher doses of theophylline; however, cigarette smoking was negatively correlated with the frequency of adverse reactions. Adverse effects were experienced by 13 percent of the nonsmokers, by 11 percent of those who smoked up to 20 cigarettes daily, and by 7 percent of those who smoked more heavily. This association was most apparent among young patients with normal renal function and was least evident among the elderly.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 630961     DOI: 10.1378/chest.73.4.455

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

Review 1.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

Review 3.  Role of tobacco smoking in pharmacokinetics.

Authors:  W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1978-02

4.  Clinical implications of Surgeon General's Report on Smoking and Health.

Authors: 
Journal:  J Natl Med Assoc       Date:  1979-07       Impact factor: 1.798

5.  Clinical pharmacology: drugs and the elderly.

Authors:  L E Ramsay; G T Tucker
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-10

6.  Bioavailability and pharmacokinetics of theophylline following plain uncoated and sustained-release dosage forms in relation to smoking habit. II. Multiple dose study.

Authors:  T Ishizaki; Y Horai; T Sasaki; K Chiba; A Ohnishi; T Suganuma; G Tsujimoto; H Echizen; T Okaniwa
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease.

Authors:  G E Marlin; M A Butcher; J A Klumpp; P J Thompson
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

8.  The role of the liver in theophylline elimination.

Authors:  R E Brashear; R L Nelson; M R Glick; T O Oei; R E DeAtley
Journal:  Lung       Date:  1980       Impact factor: 2.584

Review 9.  Drug interactions with tobacco smoking. An update.

Authors:  S Zevin; N L Benowitz
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

10.  Induction of cytochrome P-448 iso-enzymes and related glucuronyltransferases in the human liver by cigarette smoking.

Authors:  R Fleischmann; H Remmer; U Stärz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.